Cabio Biotech (Wuhan) Revenue

Cabio Biotech (Wuhan) had revenue of 155.97M CNY in the quarter ending March 31, 2025, with 33.28% growth. This brings the company's revenue in the last twelve months to 594.54M, up 25.68% year-over-year. In the year 2024, Cabio Biotech (Wuhan) had annual revenue of 555.59M with 25.19% growth.

Revenue (ttm)

594.54M

Revenue Growth

+25.68%

P/S Ratio

7.13

Revenue / Employee

1.05M

Employees

565

Market Cap

4.24B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	555.59M	111.79M	25.19%
Dec 31, 2023	443.80M	10.38M	2.39%
Dec 31, 2022	433.42M	82.32M	23.44%
Dec 31, 2021	351.11M	27.65M	8.55%
Dec 31, 2020	323.46M	11.91M	3.82%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Jiangsu Hengrui Medicine	29.19B
Shenzhen Mindray Bio-Medical Electronics	35.59B
WuXi AppTec	39.59B
Zhangzhou Pientzehuang Pharmaceutical.,	10.76B
Aier Eye Hospital Group	21.81B
Sichuan Biokin Pharmaceutical	5.82B
Shanghai United Imaging Healthcare	10.43B
Yunnan Baiyao Group Co.,Ltd	40.10B

Revenue Rankings